Who Can Be A Defendant In Biosimilar Patent Litigation?
Can a party that did not submit an abbreviated biologics license application or an abbreviated new drug application, but will market the biosimilar or generic product after U.S. Food and Drug...To view the full article, register now.
Already a subscriber? Click here to view full article